Bullous pemphigoid: therapeutic algorithm and practical management

Bibliography

• Jung M, Kippes W, Messer G, et al. Increased risk of bullous pemphigoid in male and very old patients: a population-based study on incidence. J Am Acad Dermatol 1999;41(2 Pt 1):266-8
   PubMed Web of Science ®Google Scholar
• Marazza G, Pham HC, Scharer L, et al. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol 2009;161(4):861-8
   PubMed Web of Science ®Google Scholar
• Korman N. Bullous pemphigoid. J Am Acad Dermatol 1987;16(5 Pt 1):907-24
   Google Scholar
• Langan SM, Smeeth L, Hubbard R, et al. Bullous pemphigoid and pemphigus vulgaris–incidence and mortality in the UK: population based cohort study. BMJ 2008;337:a180
   PubMed Web of Science ®Google Scholar
• Bernard P, Vaillant L, Labeille B, et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol 1995;131(1):48-52
   PubMed Web of Science ®Google Scholar
• Schmidt E, della Torre R, Borradori L. Clinical features and practical diagnosis of bullous pemphigoid. Dermatol Clin 2011;29(3):427-38; viii-ix
   Google Scholar
• Joly P, Baricault S, Sparsa A, et al. Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol 2012;132(8):1998-2004
   PubMed Web of Science ®Google Scholar
• Waisbourd-Zinman O, Ben-Amitai D, Cohen AD, et al. Bullous pemphigoid in infancy: clinical and epidemiologic characteristics. J Am Acad Dermatol 2008;58(1):41-8
   Google Scholar
• Chimanovitch I, Hamm H, Georgi M, et al. Bullous pemphigoid of childhood: autoantibodies target the same epitopes within the NC16A domain of BP180 as autoantibodies in bullous pemphigoid of adulthood. Arch Dermatol 2000;136(4):527-32
   PubMedGoogle Scholar
• della Torre R, Combescure C, Cortes B, et al. Clinical presentation and diagnostic delay in bullous pemphigoid: a prospective nationwide cohort. Br J Dermatol 2012;167(5):1111-17
   PubMed Web of Science ®Google Scholar
• Venning VA, Taghipour K, Mohd Mustapa MF, et al. British association of Dermatologists' guidelines for the management of bullous pemphigoid 2012. Br J Dermatol 2012;167(6):1200-14
   Google Scholar
• Taghipour K, Chi CC, Vincent A, et al. The association of bullous pemphigoid with cerebrovascular disease and dementia: a case-control study. Arch Dermatol 2010;146(11):1251-4
   PubMedGoogle Scholar
• Bastuji-Garin S, Joly P, Lemordant P, et al. Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Invest Dermatol 2011;131(3):637-43
   PubMed Web of Science ®Google Scholar
• Langan SM, Groves RW, West J. The relationship between neurological disease and bullous pemphigoid: a population-based case-control study. J Invest Dermatol 2011;131(3):631-6
   PubMed Web of Science ®Google Scholar
• Cordel N, Chosidow O, Hellot MF, et al. Neurological disorders in patients with bullous pemphigoid. Dermatology 2007;215(3):187-91
   Google Scholar
• Chen YJ, Wu CY, Lin MW, et al. Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study. Br J Dermatol 2011;165(3):593-9
   PubMed Web of Science ®Google Scholar
• Koerber WA Jr, Price NM, Watson W. Coexistent psoriasis and bullous pemphigoid: a report of six cases. Arch Dermatol 1978;114(11):1643-6
   Google Scholar
• Marzano AV, Trevisan V, Eller-Vainicher C, et al. Evidence for vitamin D deficiency and increased prevalence of fractures in autoimmune bullous skin diseases. Br J Dermatol 2012;167(3):688-91
   Google Scholar
• Tukaj S, Schmidt E, Recke A, et al. Vitamin D status in bullous pemphigoid patients. Br J Derm 2013;168(4):873-4
   PubMed Web of Science ®Google Scholar
• Chorzelski TP, Jablonska S, Maciejowska E, et al. Coexistence of malignancies with bullous pemphigoid. Arch Dermatol 1978;114(6):964
   Google Scholar
• Stone SP, Schroeter AL. Bullous pemphigoid and associated malignant neoplasms. Arch Dermatol 1975;111(8):991-4
   Google Scholar
• Lindelof B, Islam N, Eklund G, et al. Pemphigoid and cancer. Arch Dermatol 1990;126(1):66-8
   Google Scholar
• Stoll DM, King LE Jr. Association of bullous pemphigoid with systemic lupus erythematosus. Arch Dermatol 1984;120(3):362-6
   Google Scholar
• Grattan CE. Evidence of an association between bullous pemphigoid and psoriasis. Br J Dermatol 1985;113(3):281-3
   Google Scholar
• Giannini JM, Callen JP, Gruber GG. Bullous pemphigoid and rheumatoid arthritis. J Am Acad Dermatol 1981;4(6):695-7
   Google Scholar
• Marzano AV, Tedeschi A, Polloni I, et al. Prothrombotic state and impaired fibrinolysis in bullous pemphigoid, the most frequent autoimmune blistering disease. Clin Exp Immunol 2013;171(1):76-81
   PubMed Web of Science ®Google Scholar
• Savin JA. Death in bullous pemphigoid. Clin Dermatol 1987;5(1):52-9
   Google Scholar
• Cortes B, Marazza G, Naldi L, et al. Mortality of bullous pemphigoid in Switzerland: a prospective study. Br J Dermatol 2011;165(2):368-74
   Google Scholar
• Roujeau JC, Lok C, Bastuji-Garin S, et al. High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol 1998;134(4):465-9
   PubMedGoogle Scholar
• Parker SR, Dyson S, Brisman S, et al. Mortality of bullous pemphigoid: an evaluation of 223 patients and comparison with the mortality in the general population in the United States. J Am Acad Dermatol 2008;59(4):582-8
   Google Scholar
• Murrell DF, Daniel BS, Joly P, et al. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol 2012;66(3):479-85
   Google Scholar
• Kirtschig G, Middleton P, Bennett C, et al. Interventions for bullous pemphigoid. Cochrane Database Syst Rev 2010;10:CD002292
   Google Scholar
• Hernandez-Diaz S, Rodriguez LA. Steroids and risk of upper gastrointestinal complications. Am J Epidemiol 2001;153(11):1089-93
   PubMed Web of Science ®Google Scholar
• Frew JW, Murrell DF. Corticosteroid use in autoimmune blistering diseases. Immunol Allergy Clin North Am 2012;32(2):283-94; vii
   PubMed Web of Science ®Google Scholar
• Morel P, Guillaume JC. Treatment of bullous pemphigoid with prednisolone only: 0.75 mg/kg/day versus 1.25 mg/kg/day. A multicenter randomized study. Ann Dermatol Venereol 1984;111(10):925-8
   PubMed Web of Science ®Google Scholar
• Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002;346(5):321-7
   PubMed Web of Science ®Google Scholar
• Joly P, Roujeau JC, Benichou J, et al. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol 2009;129(7):1681-7
   PubMed Web of Science ®Google Scholar
• Kolbach DN, Remme JJ, Bos WH, et al. Bullous pemphigoid successfully controlled by tetracycline and nicotinamide. Br J Dermatol 1995;133(1):88-90
   Google Scholar
• Shiohara J, Yoshida K, Hasegawa J, et al. Tetracycline and niacinamide control bullous pemphigoid but not pemphigus foliaceus when these conditions coexist. J Dermatol 2010;37(7):657-61
   Google Scholar
• Fivenson DP, Breneman DL, Rosen GB, et al. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 1994;130(6):753-8
   PubMedGoogle Scholar
• Burton JL, Harman RR, Peachey RD, et al. Azathioprine plus prednisone in treatment of pemphigoid. Br Med J 1978;2(6146):1190-1
   Google Scholar
• Greaves MW, Burton JL, Marks J, et al. Azathioprine in treatment of bullous pemphigoid. Br Med J 1971;1(5741):144-5
   Google Scholar
• Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol 2007;143(12):1536-42
   Google Scholar
• Guillaume JC, Vaillant L, Bernard P, et al. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol 1993;129(1):49-53
   Google Scholar
• Gunay U, Gunduz K, Ermertcan AT, et al. Coexistence of psoriasis and bullous pemphigoid: remission with low-dose methotrexate. Cutan Ocul Toxicol 2013;32(2):168-9
   PubMed Web of Science ®Google Scholar
• Bara C, Maillard H, Briand N, et al. Methotrexate for bullous pemphigoid: preliminary study. Arch Dermatol 2003;139(11):1506-7
   PubMedGoogle Scholar
• Kwatra SG, Jorizzo JL. Bullous pemphigoid: a case series with emphasis on long-term remission off therapy. J Dermatolog Treat 2012
   Google Scholar
• Kjellman P, Eriksson H, Berg P. A retrospective analysis of patients with bullous pemphigoid treated with methotrexate. Arch Dermatol 2008;144(5):612-16
   PubMedGoogle Scholar
• Czernik A, Bystryn JC. Improvement of intravenous immunoglobulin therapy for bullous pemphigoid by adding immunosuppressive agents: marked improvement in depletion of circulating autoantibodies. Arch Dermatol 2008;144(5):658-61
   PubMedGoogle Scholar
• Harman KE, Black MM. High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases. Br J Dermatol 1999;140(5):865-74
   PubMed Web of Science ®Google Scholar
• Seidling V, Hoffmann JH, Enk AH, et al. Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse events. Acta Derm Venereol 2012; Epub ahead of print
   Google Scholar
• Roujeau JC, Guillaume JC, Morel P, et al. Plasma exchange in bullous pemphigoid. Lancet 1984;2(8401):486-8
   Google Scholar
• London VA, Kim GH, Fairley JA, et al. Successful treatment of bullous pemphigoid with omalizumab. Arch Dermatol 2012;148(11):1241-3
   PubMedGoogle Scholar
• Gurcan HM, Ahmed AR. Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data. Am J Clin Dermatol 2009;10(6):383-96
   Google Scholar
• Schmidt E, Kraensel R, Goebeler M, et al. Treatment of bullous pemphigoid with dapsone, methylprednisolone, and topical clobetasol propionate: a retrospective study of 62 cases. Cutis 2005;76(3):205-9
   Google Scholar
• Bouscarat F, Chosidow O, Picard-Dahan C, et al. Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases. J Am Acad Dermatol 1996;34(4):683-4
   Google Scholar
• Milligan A, Hutchinson PE. The use of chlorambucil in the treatment of bullous pemphigoid. J Am Acad Dermatol 1990;22(5 Pt 1):796-801
   Google Scholar
• Chave TA, Mortimer NJ, Shah DS, et al. Chlorambucil as a steroid-sparing agent in bullous pemphigoid. Br J Dermatol 2004;151(5):1107-8
   Google Scholar
• Cortes B, Khelifa E, Clivaz L, et al. Mortality rate in bullous pemphigoid: a retrospective monocentric cohort study. Dermatology 2012;225(4):320-5
   Google Scholar
• Thivolet J, Barthelemy H, Rigot-Muller G, et al. Effects of cyclosporin on bullous pemphigoid and pemphigus. Lancet 1985;1(8424):334-5
   Google Scholar
• Venning VA, Millard PR, Wojnarowska F. Dapsone as first line therapy for bullous pemphigoid. Br J Dermatol 1989;120(1):83-92
   Google Scholar
• Chu J, Bradley M, Marinkovich MP. Topical tacrolimus is a useful adjunctive therapy for bullous pemphigoid. Arch Dermatol 2003;139(6):813-15
   Google Scholar
• Curley RK, Holden CA. Steroid-resistant bullous pemphigoid treated with cyclosporin A. Clin Exp Dermatol 1991;16(1):68-9
   Google Scholar
• Itoh T, Hosokawa H, Shirai Y, et al. Successful treatment of bullous pemphigoid with pulsed intravenous cyclophosphamide. Br J Dermatol 1996;134(5):931-3
   Google Scholar
• Dawe RS, Naidoo DK, Ferguson J. Severe bullous pemphigoid responsive to pulsed intravenous dexamethasone and oral cyclophosphamide. Br J Dermatol 1997;137(5):826-7
   Google Scholar
• Reguiai Z, Tchen T, Perceau G, et al. Efficacy of rituximab in a case of refractory bullous pemphigoid. Ann Dermatol Venereol 2009;136(5):431-4
   Google Scholar
• Kasperkiewicz M, Shimanovich I, Ludwig RJ, et al. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol 2011;65(3):552-8
   PubMed Web of Science ®Google Scholar
• Schulze J, Bader P, Henke U, et al. Severe bullous pemphigoid in an infant–successful treatment with rituximab. Pediatr Dermatol 2008;25(4):462-5
   Google Scholar
• Daniel BS, Borradori L, Hall RP III, et al. Evidence-based management of bullous pemphigoid. Dermatol Clin 2011;29(4):613-20
   Google Scholar
• Joly P, Benichou J, Saiag P, et al. Response to: mortality rate of bullous pemphigoid in a US medical center. J Invest Dermatol 2005;124(3):664-5
   Google Scholar
• Garcia-Doval I, Conde Taboada A, Cruces Prado MJ. Sepsis associated with dermatologic hospitalization is not the cause of high mortality of bullous pemphigoid in Europe. J Invest Dermatol 2005;124(3):666-7
   Google Scholar
• Rzany B, Partscht K, Jung M, et al. Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. Arch Dermatol 2002;138(7):903-8
   PubMedGoogle Scholar
• Bernard P, Reguiai Z, Tancrede-Bohin E, et al. Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospective, cohort study. Arch Dermatol 2009;145(5):537-42
   PubMedGoogle Scholar